Klausen I C, Hegedüs L, Hansen P S, Nielsen F E, Gerdes L U, Faergeman O
Department of Internal Medicine and Cardiology A, Aarhus Amtssygehus, University of Aarhus, Denmark.
J Mol Med (Berl). 1995 Jan;73(1):41-6. doi: 10.1007/BF00203618.
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL) particle in which apolipoprotein B-100 (apoB) is attached to a glycoprotein called apolipoprotein(a) [apo(a)]. Apo(a) has several genetically determined phenotypes differing in molecular weight, to which Lp(a) concentrations in plasma are inversely correlated. High plasma levels of Lp(a) are associated with atherosclerotic diseases. It is therefore of interest to study whether factors other than the apo(a) gene locus are involved in the regulation of Lp(a) concentrations. We measured plasma concentrations of Lp(a) and other lipoproteins and determined apo(a) phenotypes in 31 patients with hyperthyroidism, before and after the patients had become euthyroid by treatment. The mean concentration of LDL cholesterol rose from 2.67 to 3.88 mmol/l (P < 0.01), apoB rose from 0.79 to 1.03 g/l (P < 0.01), and the median Lp(a) concentration increased from 9.74 to 18.97 mg/dl (P < 0.01) on treatment. Lp(a) concentrations were inversely associated to the size of the apo(a) molecule both before (P < 0.01) and after treatment (P < 0.01). The increase in Lp(a) was significant in patients with high molecular weight apo(a) phenotypes (n = 9; P < 0.01) and in patients with low molecular weight apo(a) phenotypes (n = 16; P < 0.01), but not in those with apo(a) "null types" (n = 6; P = 0.5). The low levels LDL cholesterol and apoB in untreated hyperthyroidism may result from increased LDL receptor activity. The increase in Lp(a) levels were not correlated with the increase in LDL cholesterol or apoB.(ABSTRACT TRUNCATED AT 250 WORDS)
脂蛋白(a)[Lp(a)]是一种低密度脂蛋白(LDL)颗粒,其中载脂蛋白B-100(apoB)与一种名为载脂蛋白(a)[apo(a)]的糖蛋白相连。Apo(a)有几种由基因决定的表型,分子量不同,血浆中Lp(a)浓度与之呈负相关。血浆Lp(a)水平升高与动脉粥样硬化疾病有关。因此,研究apo(a)基因位点以外的因素是否参与Lp(a)浓度的调节很有意义。我们测量了31例甲状腺功能亢进患者治疗前后甲状腺功能正常时血浆Lp(a)和其他脂蛋白的浓度,并确定了apo(a)表型。治疗后,低密度脂蛋白胆固醇的平均浓度从2.67 mmol/l升至3.88 mmol/l(P<0.01),apoB从0.79 g/l升至1.03 g/l(P<0.01),Lp(a)浓度中位数从9.74 mg/dl增至18.97 mg/dl(P<0.01)。治疗前(P<0.01)和治疗后(P<0.01),Lp(a)浓度均与apo(a)分子大小呈负相关。高分子量apo(a)表型患者(n = 9;P<0.01)和低分子量apo(a)表型患者(n = 16;P<0.01)的Lp(a)升高显著,但apo(a)“无效型”患者(n = 6;P = 0.5)无明显升高。未经治疗的甲状腺功能亢进患者低密度脂蛋白胆固醇和apoB水平较低可能是由于低密度脂蛋白受体活性增加所致。Lp(a)水平的升高与低密度脂蛋白胆固醇或apoB的升高无关。(摘要截取自250字)